---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-25-001525"
form_type: "8-K"
ticker: "LIPO"
cik: "0001347242"
company_name: "LIPELLA PHARMACEUTICALS INC."
filed_at: "2025-09-18T23:59:59+00:00"
generated_at: "2026-05-17T06:13:27.616989+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Lipella reports positive Phase 2a results for LP-10 in oral lichen planus; all efficacy endpoints met

## Summary
- All 27 patients completed 4-week treatment; no serious adverse events reported.
- 76% of tacrolimus blood measurements undetectable (<1.0 ng/mL); dry mouth in 18.5%.
- Statistically significant improvements (p<0.05) in IGA, REU, pain, sensitivity, and OLPSSM at week 4.
- Company advancing LP-10 into Phase 2b; preparing protocol with FDA feedback.

## SEC filing metadata
- accession: 0001753926-25-001525
- form_type: 8-K
- ticker: LIPO
- cik: 0001347242
- company_name: LIPELLA PHARMACEUTICALS INC.
- filed_at: 2025-09-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347242/000175392625001525/0001753926-25-001525-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347242/000175392625001525/g084955_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-25-001525
- JSON: https://secwatch.observer/filing/0001753926-25-001525.json
- Plain text: https://secwatch.observer/filing/0001753926-25-001525.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.